Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. COLLABORATION AGREEMENTCollaboration Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission.
OPTION FOR A LICENSE AGREEMENT BY AND BETWEEN MACROGENICS, INC. AND LES LABORATOIRES SERVIER AND INSTITUT DE RECHERCHES SERVIEROption for a License Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
In no event shall the total of the amounts paid under this Section 9.3.2 for the *** Licensed Program and gpA33 Licensed Program exceed ***, or exceed *** for the CD 123 Licensed Program, and exceed *** in the aggregate for all of the Licensed Programs.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. RESEARCH COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN PFIZER INC. AND MACROGENICS, INC. OCTOBER 13, 2010Research Collaboration and License Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
This Research Collaboration and License Agreement (the “Agreement”) is entered into as of October 13, 2010 (the “Effective Date”), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426, United States (“Pfizer”) and MacroGenics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 1500 East Gude Drive, Rockville, MD 20850 (“MacroGenics”). Pfizer and MacroGenics may each be referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. LICENSE AGREEMENT BY AND BETWEEN MACROGENICS, INC. AND GILEAD SCIENCES, INC.License Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
This License Agreement (this “Agreement”) is entered into and made effective as of the 3rd day of January, 2013 (the “Effective Date”), by and between MacroGenics, Inc., a corporation organized and existing under the laws of the State of Delaware, having a principal office located at 9640 Medical Center Drive, Rockville, MD 20850, USA (“MacroGenics”), and Gilead Sciences, Inc., a company organized and existing under the laws of the State of Delaware, having a principal office located at 333 Lakeside Drive, Foster City, CA 94404 (“Gilead”). MacroGenics and Gilead are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. OPTION FOR A LICENSE AGREEMENT BY AND BETWEEN MACROGENICS, INC. AND LES LABORATOIRES SERVIER AND INSTITUT DE RECHERCHES...Option for a License Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
This Option for a License Agreement (this “Agreement”) is entered into and made effective as of the 24th day of November, 2011 (the “Effective Date”), by and between MacroGenics, Inc. a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 1500 East Gude Drive Rockville, MD 20850, USA (“MacroGenics”), and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (“LLS”) and Institut de Recherches Servier, a company organized and existing under the laws of France, having a principal office located at 3 rue de la République – 92150 Suresnes - France (“IdRS” and LLS and IdRS hereinafter collectively referred to as “Servier”). MacroGenics and Servier are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
BI Contract No. 43032525 COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN BOEHRINGER INGELHEIM INTERNATIONAL GMBH AND MACROGENICS, INC. OCTOBER 18, 2010Collaboration and License Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
Subject to the terms and conditions of the Collaboration and License Agreement, dated as of , 2010 (the “Collaboration and License Agreement”) by and between Boehringer Ingelheim International GmbH and MacroGenics, Inc., MacroGenics has the option to co-promote up to *** Products in the United States (the “Co-Promotion Territory”) by providing at least *** and up to *** of the total Details for such Product to only one class of specialty physicians (“Co-Promotion Audience”) in the Co-Promotion Territory in accordance with the brand plan developed and approved annually by BI. This Exhibit outlines the framework for the co-promotion rights to be negotiated in good faith by the Parties upon exercise by MacroGenics of its Co-Promotion Option pursuant to Section 4.5 of the Collaboration and License Agreement, which framework the Parties agree will be reflected in a definitive co-promotion agreement (“Co-Promotion Agreement”). All capitalized terms not otherwise defined shall have the meanin
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Triple asterisks denote omissions. FIRST AMENDMENT (“Amendment No. 1”)License Agreement • October 4th, 2013 • Macrogenics Inc • Pharmaceutical preparations
This first amendment, effective as of October 1, 2013 (“Amendment No. 1 Effective Date”), to the LICENSE AGREEMENT BY AND BETWEEN MACROGENICS, INC. AND GILEAD SCIENCES, INC. dated as of January 3, 2013 (the “Agreement”), by and between GILEAD SCIENCES, INC., a Delaware Corporation (“Gilead”), on the one hand, and MACROGENICS, INC., a Delaware corporation, on the other hand (“MacroGenics”). Capitalized terms used but not defined herein shall have the meanings assigned them in the Agreement.
